Table 2.
Baseline characteristics of interest for the TPCP cohort.
| TPCP Cohort | ||
| n = 891 | % | |
|---|---|---|
| Pathology Division | ||
| Division I | 556 | 62.4 |
| Division II | 335 | 37.6 |
| Age at Diagnosis (years) | ||
| Median (IQR) | 70 (64, 74) | – |
| Year of Diagnosis | ||
| 2008 – 2010 | 539 | 60.5 |
| 2011 – 2013 | 352 | 39.5 |
| PSA (ng/mL) | ||
| Median (IQR) | 6.7 (5.0, 10.0) | – |
| Missing | 23 | – |
| Previous Negative Biopsies | ||
| 0 | 702 | 79.7 |
| 1 | 130 | 14.8 |
| ≥ 2 | 49 | 5.6 |
| Missing | 10 | – |
| Number of cores samples at biopsy | ||
| Median (IQR) | 14.0 (12.0, 17.0) | |
| ISUP Grade (based on the pathology reports) | ||
| 1 | 276 | 31.7 |
| 2 | 293 | 33.6 |
| 3 | 173 | 19.9 |
| 4 | 71 | 8.2 |
| 5 | 58 | 6.7 |
| Not evaluablea | 20 | – |
| ISUP Grade (based on the centralized histopathological review) | ||
| 1 | 125 | 14.2 |
| 2 | 289 | 32.7 |
| 3 | 167 | 18.9 |
| 4 | 222 | 25.1 |
| 5 | 80 | 9.1 |
| Not evaluablea | 8 | – |
| Comorbiditiesb | ||
| Myocardial Infarction | 21 | 2.4 |
| Congestive Heart Failure | 13 | 1.5 |
| Peripheral Vascular Disease | 21 | 2.4 |
| Cerebrovascular Disease | 15 | 1.7 |
| Chronic Pulmonary Disease | 24 | 2.7 |
| Liver Disease (Mild) | 9 | 1.0 |
| Diabetes (Mild to Moderate) | 19 | 2.1 |
| Renal Disease | 16 | 1.8 |
| Any Malignancy (including Lymphoma and Leukaemia) | 44 | 4.9 |
| Metastatic Solid Tumour | 9 | 1.0 |
| Otherc | 5 | 0.6 |
| Charlson-Romano Comorbidity Index | ||
| 0 | 447 | 50.2 |
| 1 | 36 | 4.0 |
| 2 | 51 | 5.7 |
| ≥3 | 35 | 3.9 |
| Without previous admission | 322 | 36.1 |
| Digital Rectal Examination | ||
| Negative | 392 | 52.7 |
| Positive | 352 | 47.3 |
| Missing | 147 | – |
| Imaging | ||
| Positive TRUSd | 184 | 20.7 |
| Positive MRIe | 50 | 5.6 |
| Primary Radical Treatment (within six months) | ||
| Radical Prostatectomy | 361 | 40.5 |
| Radical Prostatectomy & Radiotherapy | 36 | 4.0 |
| Radical Radiotherapy | 137 | 15.4 |
| Deferredf | 373 | 41.9 |
| Other Treatments (within six months) | ||
| Androgen Deprivation Therapy | 124 | 13.9 |
| Main cT | ||
| cT1 | 366 | 44.5 |
| cT2 | 288 | 35.0 |
| cT3 | 169 | 20.5 |
| Missing | 68 | – |
| Detailed cT | ||
| cT1c | 366 | 44.5 |
| cT2a | 106 | 12.9 |
| cT2b | 39 | 4.7 |
| cT2ab | 39 | 4.7 |
| cT2c | 104 | 12.6 |
| cT3+ | 169 | 20.5 |
| Missing | 68 | – |
| Social Deprivation Index | ||
| Low | 280 | 31.4 |
| Medium | 280 | 31.4 |
| High | 331 | 37.1 |
IQR, Interquartile Range (25th, 75th percentile); PSA, Prostate-Specific Antigen; ISUP, International Society of Urological Pathology; MRI, Magnetic Resonance Imaging; TRUS, Transrectal Ultrasonography.
ISUP score for patients with a tumor area of less than 5% was not evaluable.
Each patient in the study population may have experienced multiple comorbidities or no comorbidities (n = 447).
Comorbidities with a prevalence of less than 1%: Dementia, Rheumatic Disease, Peptic Ulcer Disease, Diabetes (with Chronic Complications), Hemiplegia or Paraplegia, Liver Disease (Moderate to Severe), HIV/AIDS.
Positivity as reported in the clinical records. All remaining patients had a reported negative TRUS, or no information reported in their records regarding the TRUS.
Positivity as reported in the clinical records (i.e., suspected abnormal area). All remaining patients had a reported negative MRI, or no information reported in their records regarding the MRI.
Deferred treatment includes active surveillance or watchful waiting.
Percentages may not total 100% because of rounding.